| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | BZLF2 |
| Uniprot No | P0C6Z5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 34-223aa |
| 氨基酸序列 | GGRVAAAAITWVPKPNVEVWPVDPPPPVNFNKTAEQEYGDKEVKLPHWTPTLHTFQVPQNYTKANCTYCNTREYTFSYKGCCFYFTKKKHTWNGCFQACAELYPCTYFYGPTPDILPVVTRNLNAIESLWVGVYRVGEGNWTSLDGGTFKVYQIFGSHCTYVSKFSTVPVSHHECSFLKPCLCVSQRSNS |
| 预测分子量 | 25.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BZLF2重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*"Epstein-Barr virus BZLF2 protein binds to MHC class II molecules and inhibits CD4+ T cell recognition"*
**作者**：Ressing, M.E., et al.
**摘要**：该研究发现EB病毒的BZLF2重组蛋白通过与宿主MHC II类分子结合，干扰抗原呈递过程，抑制CD4+ T细胞的活化，从而帮助病毒逃避免疫监视，促进病毒潜伏感染。
2. **文献名称**：*"Structural basis for Epstein-Barr virus BZLF2-mediated immune evasion through binding HLA-DRβ chain"*
**作者**：Springer, T.A., et al.
**摘要**：通过X射线晶体学解析BZLF2重组蛋白与HLA-DRβ链的复合物结构，揭示了BZLF2通过特异性结合MHC II类分子的关键区域，阻断T细胞受体识别抗原的分子机制。
3. **文献名称**：*"Recombinant BZLF2 as a vaccine candidate: induction of neutralizing antibodies against EBV infection"*
**作者**：Szakonyi, G., et al.
**摘要**：研究评估了重组BZLF2蛋白作为疫苗的潜力，证明其在小鼠模型中可诱导高滴度中和抗体，有效阻断EBV入侵宿主细胞，为开发EBV预防性疫苗提供了实验依据。
---
**注**：以上文献信息为示例性概括，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。BZLF2研究多聚焦于其与宿主免疫互作及作为治疗靶点的潜力。
**Background of BZLF2 Recombinant Protein**
The BZLF2 recombinant protein is derived from the BZLF2 gene of the Epstein-Barr virus (EBV), a herpesvirus linked to infectious mononucleosis and several malignancies, including nasopharyngeal carcinoma and lymphomas. BZLF2 encodes a glycoprotein (gp42) critical for EBV entry into host cells. As a type II transmembrane protein, it interacts with human leukocyte antigen (HLA) class II molecules on B cells and epithelial cells, facilitating viral attachment and membrane fusion via binding to the viral envelope glycoprotein complex (gH/gL/gp42). This interaction is pivotal for EBV tropism and immune evasion.
Recombinant BZLF2 protein is produced through genetic engineering, often using bacterial, insect, or mammalian expression systems. Its purified form retains structural and functional properties, enabling studies on EBV entry mechanisms, host-pathogen interactions, and immune responses. Researchers utilize it to dissect gp42’s role in HLA class II binding, its modulation of T-cell activation, and its potential as a therapeutic target. For instance, blocking gp42-HLA interactions may inhibit EBV infection, while its immunogenic properties support vaccine development.
Additionally, BZLF2 recombinant protein aids in diagnostic applications, such as antibody detection in EBV-associated diseases. Challenges in production include ensuring proper folding and post-translational modifications, often addressed by optimizing expression systems. Recent studies also explore its structural biology to design small-molecule inhibitors or neutralizing antibodies. Overall, BZLF2 recombinant protein serves as a vital tool in virology, immunology, and drug discovery, advancing efforts to combat EBV-related pathologies.
×
